Monday, March 4, 2013
GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.
GNS Healthcare, a healthcare analytics company focused on enabling personalized medicine to improve human health, has entered into a collaboration with Bristol-Myers Squibb focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation. Utilizing its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms.
Using a patient dataset and high-horsepower computing, researchers at Biogen Idec and analytics company GNS Healthcare have built a rheumatoid arthritis disease model that lets them run patient-specific virtual clinical trials, according to Fierce Biotech IT. This personalized-medicine stepping stone yields dynamic disease models of individualized patient outcomes.